Fig. 5.

Western blot of the fusion and original PCC subunits after delivery to defective lymphocyte cells. Extracted mitochondria and cytosol fractions were analyzed on 12% SDS-PAGE and probed with PCCA and PCCB antibodies. (a) PCCA defective cells treated with TAT-PCCA and TAT-MTS-PCCA are compared with normal lymphocytes and un-treated cells. (b) PCCB defective cells treated with PCCB, PCCB-TAT and PCCB-MTS-TAT are compared with normal lymphocytes and un-treated cells. The purity of the sub-cellular fractions was confirmed using the mitochondrial marker E1α (43 kDa). ImageJ densitometry analysis (National Institutes of Health (NIH) ImageJ 1.47 software) results are presented below each image. Intensity ratio of PCCA and PCCB bands relative to the E1α bands in A and B respectively presented as AUC ratio of corresponding intensity peak (AUC ratio mean ± SD). Anti-chicken HRP conjugated IgG (bovine) and anti-mouse HRP conjugated IgG (goat) (Santa Cruz Biotechnology, CA, USA) were used as secondary antibodies for probing PCCA and PCCB antibodies respectively. PCCA def: PCCA defective lymphocytes, PCCB def: PCCB defective lymphocytes, normal lymph: normal lymphocytes.